Ontario researchers have developed a genetic test to identify which men are at highest risk for recurrence of prostate cancer following localized treatment with surgery or radiation therapy.
Researchers at the Ontario Institute for Cancer Research and Toronto's University Health Network say the test quickly determines which men with prostate cancer would do well with only surgery or radiation, and those who would need additional treatment.
The findings are described in the online edition of the journal Lancet Oncology.
An estimated 23-thousand-600 Canadian men will be diagnosed this year with prostate cancer, the most common cancer diagnosed in men and the third leading cause of death from cancer.
